A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes

American Journal of Human Genetics

Volumn 81, Issue 5, 2007, Pages 873-883

  Easton, Douglas F ^a   Deffenbaugh, Amie M ^b   Pruss, Dmitry ^b   Frye, Cynthia ^b   Wenstrup, Richard J ^b   Allen Brady, Kristina ^b   Tavtigian, Sean V ^c   Monteiro, Alvaro N A ^d   Iversen, Edwin S ^e   Couch, Fergus J ^f   Goldgar, David E ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e DUKE UNIVERSITY   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; FAMILY HISTORY; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC VARIABILITY; LOGISTIC REGRESSION ANALYSIS; MUTATIONAL ANALYSIS; ONCOGENE; PEDIGREE ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS;

EID: 35348834779     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/521032     Document Type: Article

References (37)

1. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2 - Cancer Genetics Studies Consortium. JAMA 277:997-1003
2. Lucci-Cordisco E, Boccuto L, Neri G, Genuardi M (2006) The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in Lynch syndrome. Cancer Biomark 2:11-27
3. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ, Breast Cancer Information Core (BIC) Steering Committee (2004) Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75:535-544
4. Billack B, Monteiro AN (2004) Methods to classify BRCA1 variants of uncertain clinical significance: the more the merrier. Cancer Biol Ther 3:458-459
5. Monteiro AN, Couch FJ (2006) Cancer risk assessment at the atomic level. Cancer Res 66:1897-1899
6. Thompson D, Easton DF, Goldgar DE (2003) A full-likelihood method for the evaluation of causality of sequence variants from family data. Am J Hum Genet 73:652-655
7. Petersen GM, Parmigiani G, Thomas D (1998) Missense mutations in disease genes: a Bayesian approach to evaluate causality. Am J Hum Genet 62:1516-1524
8. Zhou XI, Iversen ES Jr, Parmigiani G (2005) Classification of missense mutations of disease genes. J Am Stat Assn 100:51-60
9. Judkins T, Hendrickson BC, Deffenbaugh AM, Eliason K, Leclair B, Norton MJ, Ward BE, Pruss D, Scholl T (2005) Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res 65:10096-10103
10. Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, Tavtigian SV (2004) Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41:492-507
11. Tavtigian SV, Samollow PB, de Silva D, Thomas A (2006) An analysis of unclassified missense substitutions in human BRCA1. Fam Cancer 5:77-88
12. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43:295-305
13. Miller MP, Kumar S (2001) Understanding human disease mutations through the use of interspecific genetic variation. Hum Mol Genet 10:2319-2328
14. Sunyaev S, Ramensky V, Koch I, Lathe WIII, Kondrashov AS, Bork P (2001) Prediction of deleterious human alleles. Hum Mol Genet 10:591-597
15. Grantham R (1974) Amino acid difference formula to help explain protein evolution. Science 185:862-864
16. Chapman MS, Verma IM (1996) Transcriptional activation by BRCA1. Nature 382:678-679
17. Monteiro AN, August A, Hanafusa H (1996) Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 93:13595-13599
18. Ostrow KL, McGuire V, Whittemore AS, DiCioccio RA (2004) The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity. Cancer Genet Cytogenet 153:177-180
19. Phelan CM, Dapic V, Tice B, Favis R, Kwan E, Barany F, Manoukian S, Radice P, van der Luijt RB, van Nesselrooij BP, et al (2005) Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet 42:138-146
20. Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, Swaby RF, Urmenyi TP, Rondinelli E, Silva R, Gayol L, et al (2007) Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67:1494-1501
21. Morris JR, Pangon L, Boutell C, Katagiri T, Keep NH, Solomon E (2006) Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet 15:599-606
22. Wu K, Hinson SR, Ohashi A, Farrugia DJ, Wendt P, Tavtigian SV, Deffenbaugh A, Goldgar D, Couch FJ (2005) Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 65:417-426
23. Mirkovic N, Marti-Renom MA, Weber BL, Sali A, Monteiro AN (2004) Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 64:3790-3797
24. Karchin R, Monteiro AN, Tavtigian SV, Carvalho MA, Sali A (2007) Functional impact of missense variants in BRCA1 predicted by supervised learning. PLoS Comput Biol 3:e26
25. Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thoma NH, Zheng N, Chen PL, Lee WH, Pavletich NP (2002) BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297:1837-1848
26. Hohenstein P, Kielman MF, Breukel C, Bennett LM, Wiseman R, Krimpenfort P, Cornelisse C, van Ommen GJ, Devilee P, Fodde R (2001) A targeted mouse BRCA1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene 20:2544-2550
27. Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH (1996) Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 12:191-194
28. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, et al (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606-609
29. Alter BP, Rosenberg PS, Brody LC (2007) Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 44:1-9
30. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130 (erratum 73:209)
31. Lathrop GM, Lalouel JM, Julier C, Ott J (1984) Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci USA 81:3443-3446
32. Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318
33. Smith SA, Easton DF, Evans DG, Ponder BA (1992) Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 2:128-131
34. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, Ormiston W, Daly PA, Ford D, Easton DF, et al (1995) Consistent loss of the wild-type allele in breast cancers from a family linked to the Brca2 gene on chromosome 13q12-13. Oncogene 10:1673-1675
35. Osorio A, Milne RL, Honrado E, Barroso A, Diez O, Salazar R, de la Hoya M, Vega A, Benitez J (2007) Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information. Hum Mutat 28:477-485
36. Lovelock PK, Healey S, Au W, Sum EY, Tesoriero A, Wong EM, Hinson S, Brinkworth R, Bekessy A, Diez O, et al (2006) Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 43:74-83
37. Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, et al (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66:2019-2027